Exact Sciences (NASDAQ:EXAS) Reaches New 12-Month Low at $33.31

Exact Sciences Co. (NASDAQ:EXASGet Rating) reached a new 52-week low during trading on Friday . The company traded as low as $33.31 and last traded at $33.66, with a volume of 9864 shares traded. The stock had previously closed at $34.35.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Citigroup decreased their price target on Exact Sciences from $65.00 to $50.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 3rd. Raymond James decreased their price objective on Exact Sciences from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 3rd. Evercore ISI increased their price objective on Exact Sciences to $65.00 in a research report on Tuesday, August 9th. Piper Sandler decreased their price objective on Exact Sciences from $50.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 17th. Finally, Benchmark decreased their price objective on Exact Sciences to $54.00 in a research report on Tuesday, August 9th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $69.14.

Exact Sciences Stock Performance

The stock has a 50 day moving average price of $41.42 and a two-hundred day moving average price of $50.40. The company has a current ratio of 2.48, a quick ratio of 2.23 and a debt-to-equity ratio of 0.70. The company has a market cap of $5.98 billion, a price-to-earnings ratio of -8.12 and a beta of 1.37.

Insider Activity

In related news, Director Katherine S. Zanotti sold 4,608 shares of the firm’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the sale, the director now owns 60,318 shares of the company’s stock, valued at approximately $2,722,754.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Katherine S. Zanotti sold 4,608 shares of the firm’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the sale, the director now owns 60,318 shares of the company’s stock, valued at approximately $2,722,754.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Katherine S. Zanotti sold 1,086 shares of the firm’s stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $40.13, for a total value of $43,581.18. Following the sale, the director now directly owns 60,318 shares in the company, valued at approximately $2,420,561.34. The disclosure for this sale can be found here. Insiders have sold a total of 5,701 shares of company stock valued at $251,872 in the last 90 days. 1.30% of the stock is owned by company insiders.

Institutional Trading of Exact Sciences

Hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. increased its holdings in Exact Sciences by 26.6% during the 4th quarter. Itau Unibanco Holding S.A. now owns 633 shares of the medical research company’s stock worth $49,000 after purchasing an additional 133 shares in the last quarter. Prospera Financial Services Inc increased its holdings in Exact Sciences by 5.1% during the 1st quarter. Prospera Financial Services Inc now owns 3,558 shares of the medical research company’s stock worth $249,000 after purchasing an additional 174 shares in the last quarter. Koshinski Asset Management Inc. increased its holdings in Exact Sciences by 45.5% during the 1st quarter. Koshinski Asset Management Inc. now owns 640 shares of the medical research company’s stock worth $45,000 after purchasing an additional 200 shares in the last quarter. Steward Partners Investment Advisory LLC increased its holdings in Exact Sciences by 44.4% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 667 shares of the medical research company’s stock worth $26,000 after purchasing an additional 205 shares in the last quarter. Finally, Quantum Private Wealth LLC increased its holdings in Exact Sciences by 0.4% during the 1st quarter. Quantum Private Wealth LLC now owns 61,248 shares of the medical research company’s stock worth $4,282,000 after purchasing an additional 225 shares in the last quarter. Institutional investors and hedge funds own 90.95% of the company’s stock.

About Exact Sciences

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Featured Stories

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.